Previous 10 | Next 10 |
home / stock / dmttf / dmttf news
Reporting its financial results and continued p rogress across short-acting psychedelics portfolio Executive team and IP position strengthened LONDON, June 09, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Com...
LONDON, May 30, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that P...
- Appointment of Alastair Riddell as COO - Two new Composition of Matter patents granted for pipeline projects - Progress continues across short-acting psychedelics portfolio LONDON, May 25, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the ...
LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, will participate in t...
Small Pharma (OTC: DMTTF), a London-based neuropharmaceutical company focused on psychedelic-assisted therapies, made big news recently with the announcement of the first clinical trial in February 2021, using N, N-Dimethyltryptamine ( DMT ) to treat major depres...
NEW YORK, April 29, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the April 27 th and 28 th KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing....
LONDON, April 27, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, announces that...
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences , the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Co...
Lead DMT-assisted therapy candidate SPL026’s clinical development program strengthened with the addition of two clinical trials planned for 2022 SPL028, a deuterated DMT candidate with Composition of Matter patent protection in the UK, moves towards Phase I clinical trial...
LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuroscience company focused on psychedelic-assisted therapies for mental health conditions, announces its participation in th...
News, Short Squeeze, Breakout and More Instantly...
2024-03-27 17:08:02 ET The world is facing a mental health crisis. Today, one in six individuals are likely to suffer from an episode of major depression during their lifetime that could significantly impact their relationships, work and health. Add to that the substantial negative impact t...
2024-03-27 17:08:02 ET Help for mental health sufferers Small Pharma is a neuropharmaceutical company. They specialize in IP led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into DMT-assiste...
Cybin (NYSE American: CYBN) (NEO: CYBN) together with Small Pharma Inc. (TSX.V: DMT) (OTCQB: DMTTF) announced the completion of the previously disclosed acquisition by Cybin of Small Pharma by way of a plan of arrangement under the Business Corporations Act (British Columbia), and pursuant to ...